Navigate Up
UPMC/University of Pittsburgh Schools of the Health Sciences
For Journalists
Senior Manager
Telephone: 412-578-9193 or 412-624-3212
Manager
Telephone: 412-647-9966
For Journalists

No ‘Brakes’ — Pitt Study Finds Mechanism for Increased Activity of Oncogene in Head and Neck Cancers

 
PITTSBURGH, Jan. 6, 2014 – The increased activation of a key oncogene in head and neck cancers could be the result of mutation and dysfunction of regulatory proteins that are supposed to keep the gene, which has the potential to cause cancer, in check, according to a new study led by researchers at the University of Pittsburgh School of Medicine. The findings, published in the early online version of the Proceedings of the National Academy of Sciences, suggest a new target for drugs to treat head and neck tumors, as well as other cancers.
 
Many research teams have found activation and increased signaling of a protein known as Signal Transducer and Activator of Transcription 3 (STAT3) in different kinds of cancers, and it is associated with poor prognosis, said senior author Jennifer Grandis, M.D., Distinguished Professor of Otolaryngology, Pitt School of Medicine, and director of the Head and Neck Program at the University of Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter. In adult tissues, STAT3 triggers the production of other proteins that promote the growth and survival of cancer cells.
 
“Until now, the question of why STAT3 could be hyperactivated has gone unanswered,” Dr. Grandis said. “Our findings reveal a possible mechanism for this abnormal activity, which could help us develop new cancer drugs.”
 
Noting that gene aberrations in STAT3 itself rarely occurred in head and neck cancers, she and her colleagues looked for mutations in other proteins associated with increased activity of STAT3. To be activated, STAT3 must be phosphorylated, meaning a phosphate group is added to it. Many cancer drugs work by inhibiting enzymes called kinases that encourage this process. The team focused instead on the other side of the biochemical seesaw in which enzymes called phosphatases deactivate proteins by removing phosphates.
 
To their surprise, they found head and neck tumors with elevated STAT3 were associated with mutations in the PTPR family of phosphatases. When they reproduced the mutations in computational and lab models, they saw that they led to dysfunction of the enzymes.
 
“Because the phosphatases don’t work properly, phosphate groups don’t get removed from STAT3 appropriately, and it stays activated,” Dr. Grandis explained.  “These mutations essentially get rid of the brakes that might otherwise slow or even stop cancer development.”
 
It might be possible one day to screen tumors for mutations in the PTPR group and then treat them with drugs that inhibit STAT3’s activity, she added.
 
Co-investigators include other researchers from the University of Pittsburgh School of Medicine and the University of Pittsburgh Cancer Institute; Central European Institute of Technology at Masaryk University, Czech Republic; University of Texas MD Anderson Cancer Center; Case Western Reserve University; and the Dana-Farber Cancer Institute at Harvard Medical School.
 
The project was funded by National Institutes of Health grants CA097190, CA77308, CA137260, CA127590 and DE024007; the American Cancer Society; the Patricia L. Knebel Fund of the Pittsburgh Foundation; the Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine; and the John S. Lazo Cancer Pharmacology Fellowship.

©  UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences
Supplemental content provided by A.D.A.M. Health Solutions. All rights reserved.

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

For UPMC Mercy Patients: As a Catholic hospital, UPMC Mercy abides by the Ethical and Religious Directives for Catholic Health Care Services, as determined by the United States Conference of Catholic Bishops. As such, UPMC Mercy neither endorses nor provides medical practices and/or procedures that contradict the moral teachings of the Roman Catholic Church.

© UPMC
Pittsburgh, PA, USA UPMC.com